Anusheela Howlader

Anusheela Howlader

Auto-generated profile, based on publicly available information

Anusheela Howlader

Department of Microbiology, Aarupadai Veedu Medical College & Hospital Vinayaka Mission's Research Foundation (Deemed to be University) Kirumampakkam Puducherry India

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2025 in Health Science Reports
Verified
Journal Article
Open access
PNPRITHIVIRAJ NAGARAJAN
PRITHIVIRAJ NAGARAJAN
MRMani Rajarathinam
Mani Rajarathinam
AJArun Daniel Jayakumar
Arun Daniel Jayakumar
PTPrasad Thirumal
Prasad Thirumal
KRKumar Rangarajalu
Kumar Rangarajalu
AHAnusheela Howlader
Anusheela Howlader
Background and Aim: Diabetic foot ulcers (DFUs) pose a significant challenge in the management of chronic wounds, characterized by a high risk of infection and severe complications, including potential limb amputation. The limitations of conventional treatments have sparked interest in regenerative therapies, particularly the use of adipose‐derived stem cells (ADSCs). which possess significant potential across various medical fields for enhancing tissue repair and modulating immune responses. This perspective critically evaluates the potential of ADSCs for treating DFUs while exploring their broader implications in regenerative medicine. Methods: This perspective incorporates insights from a comprehensive literature review, with searches conducted on platforms such as Google Scholar, PubMed, and Scopus. The selected studies focus on the regenerative efficacy, safety, and clinical applications of ADSCs in wound healing, emphasizing rigorous methodologies that support reliable conclusions. Results: ADSCs exhibit significant promise in promoting tissue regeneration, stimulating angiogenesis, and modulating immune function—mechanisms that are beneficial not only for patients with DFUs but also for those with other chronic and non‐healing wounds. Nevertheless, challenges persist, including the risk of tumorigenesis, particularly in patients with a history of cancer, as well as variability in therapeutic outcomes due to donor characteristics and processing techniques. Conclusion: While ADSCs represent a promising therapeutic option for DFUs and provide valuable insights for a wider array of chronic wound therapies, their clinical application requires careful consideration of safety concerns, including risks of tumor formation and immune response issues. Future advancements in cell processing and well‐structured clinical trials will be essential to ensuring efficacy across diverse populations in the broader context of regenerative medicine.

8 November 2022 in Health Science Reports
Verified
Journal Article
Open access
PNPRITHIVIRAJ NAGARAJAN
PRITHIVIRAJ NAGARAJAN
LLLEENA RAJATHY PORT LOUIS
LEENA RAJATHY PORT LOUIS
AHAnusheela Howlader
Anusheela Howlader
KRKumar Rangarajalu
Kumar Rangarajalu

30 June 2022 in Gomal Journal of Medical Sciences
Verified
Journal Article
Open access
PDF file
PNPRITHIVIRAJ NAGARAJAN
PRITHIVIRAJ NAGARAJAN
AHAnusheela Howlader
Anusheela Howlader
KRKumar Rangarajalu
Kumar Rangarajalu
SARS-CoV-2 Omicron variant of concern (VOC) has rapidly expanded worldwide since it first emerged on November 24, 2021, in Southern Africa and has already reached every continent. Many issues surrounding Omicron remain unresolved, including the severity of the disease and the extent to which currently available vaccinations effectively prevent COVID-19 infection. Compared to the previous VOC (Delta version), more mutations were detected, which may address Omicron’s characteristics.